What is MLYS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MLYS?

P/E (TTM) is n/a and 52-week range is $21.46 to $47.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MLYS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MLYS?

The company profile lists net income (TTM) near $-374M, EPS (TTM) near $-4.24 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Mineralys Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Radnor, Pennsylvania, US, 88.1M shares outstanding, ISIN US6031701013 when available from company profile and filing metadata.

Mineralys Therapeutics Inc

$MLYS

Health Care · Biotechnology

IR Run Scenarios

$23.37

+4.42%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 76 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The company has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The company is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.

Employees

Website

mineralystx.com/

IPO

2023-02-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)